'Ras wt' presentation slideshows

K-Ras and Beyond

631 views • 46 slides

Biomarkers and personalized Therapy for CRC T. Thomaidis

Biomarkers and personalized Therapy for CRC T. Thomaidis. Colorectal cancer: Distribution. Worldwide around 1.4 mm new cases and 694.000 deaths per year. Metastasized colorectal cancer. 5-Fluorouracil & Derivate. Oxaliplatin. Irinotecan. Bevacizumab Cetuximab Panitumumab Ramucirumab.

465 views • 35 slides

Predictive Biomarkers of EGFR Targeted Therapy: Beyond KRAS

570 views • 31 slides

*: Coordinating group

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected K-ras wild type Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG).

348 views • 27 slides

2014: A new twist in the biomarker story

2014: A new twist in the biomarker story. KRAS exon 2. RAS. A new label for Erbitux. CRYSTAL: RAS wt selection extended the OS benefit with cetuximab + FOLFIRI. 1.0. Cetuximab + FOLFIRI (n=599). 1.0. FOLFIRI (n=599). 0.8. Overall patient population (ITT). 0.8. 19.9. 0.6. HR 0.878

369 views • 21 slides

Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG). Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010.

270 views • 15 slides